Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less

Lignende værker

• Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
  af: Gountas, Ilias, et al.
  Udgivet: (2019)
• HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
  af: La Manna, Gaetano
  Udgivet: (2018)
• Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
  af: Dold, L., et al.
  Udgivet: (2019)
• Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
  af: Minosse, Claudia, et al.
  Udgivet: (2021)
• Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
  af: Bartels, Doug J., et al.
  Udgivet: (2013)